India CDMO Market Size, Trends, Growth, Statistics and Report 2025-2033

India Cdmo Market Overview

The CDMO market in India size reached USD 7.9 Billion in 2024 and is expected to grow to USD 15.4 Billion by 2033, exhibiting a CAGR of 7.7% during the forecast period of 2025-2033. This growth is driven by rising demand for contract manufacturing services in pharmaceuticals, especially complex generics, HPAPIs, and sterile injectables, supported by a strong regulatory framework and cost advantages. The market also benefits from expanding global footprints catering to major pharmaceutical markets such as the U.S. and Europe.

India Cdmo Market Study Assumption Years

• Base Year : 2024

• Historical Year/Period : 2019-2024

India Cdmo Market Key Takeaways

• Current Market Size : USD 7.9 Billion

• CAGR : 7.7%

• Forecast Period : 2025-2033

• The market is propelled by increasing demand for contract development and manufacturing services in the pharmaceutical sector.

• Strong government incentives, including the Production Linked Incentive (PLI) scheme, enhance investment and market growth.

• Indian CDMOs are attracting global companies due to cost efficiency, skilled workforce, and robust regulatory frameworks.

• Expansion in biologics and biosimilars manufacturing capabilities is a significant growth driver.

• Advances in digital transformation and adoption of Industry 4.0 technologies improve operational efficiency in the market.

Request Free Sample Report: https://www.imarcgroup.com/india-cdmo-market/requestsample

India Cdmo Market Growth Factors

The India CDMO industry is able to capitalize upon India's established pharmaceutical production facilities and a large pool of scientists and engineers. Initiatives of the Indian government, such as the Production Linked Incentive (PLI) scheme, are spurring huge investments in the sector from both domestic and foreign players. India has benefited from favorable regulatory policies, which have added to this expansion.

Worldwide increased demand for cost-effective healthcare has resulted in pharmaceutical companies contracting out to CDMOs in India for manufacturing at lower costs while maintaining quality standards. As a result, India prefers to receive contract development and manufacturing services (CDMO) in the pharmaceutical industry. Domestic research and development investments also drive the market.

Sustainability and green chemistry gain momentum as pharmaceuticals are produced. Indian CDMOs in line with international trends are increasingly looking for opportunities to implement greener processes. The strong alliances with global biotech companies and increasing footprint in the emerging markets offer Indian CDMOs an opportunity to occupy prime position in the international pharmaceutical value chain.

India Cdmo Market Trends

There are different trends and outlook for the India CDMO industry. As more complex biologic drug development and manufacturing services are outsourced, the biologics and biosimilars manufacturing is expected to grow greatly. Indian CDMOs have made substantial investments in building biomanufacturing capacities (mammalian and microbial expression systems) which are helped by regulatory harmonization with the USFDA and EMA.

The pharmaceutical industry is seeking end-to-end CDMOs to support drug discovery, formulation development, clinical trial support, commercial-scale manufacturing and regulatory compliance. To cater to these demands, Indian CDMOs are expanding their services to offer solutions for AI-based drug discovery, process automation and real-time process data analytics.

As a global industry trend, digital transformation such as the use of Industry 4.0 technologies such as manufacturing execution systems, predictive analytics, IoT-enabled equipment monitoring, and blockchain can improve quality, transparency and supply chain traceability. Cloud-based collaboration platforms help manage projects and provide clients with a global view of project status and client communications. All these advances help cement the position of Indian CDMOs as technologically advanced and cost-competitive suppliers.

Buy the Full Report for Complete Data, Trends, and Opportunities: https://www.imarcgroup.com/checkout?id=30719&method=1337

India Cdmo Market Segmentation

Service Type Insights

• Contract Development Services: This segment includes preclinical development, clinical development, and analytical and bioanalytical services, providing comprehensive drug development support.

• Contract Manufacturing Services: Comprising active pharmaceutical ingredients (APIs) manufacturing, finished dosage forms (FDFs) manufacturing, biologics manufacturing, and packaging, this segment focuses on large-scale production activities.

Type Insights

• Small Molecules: Traditional chemical-based drug substances.

• Biologics: Complex drugs produced using biotechnological methods.

• Biosimilars: Biologically similar versions of biologic drugs.

• Vaccines: Pharmaceutical preparations for immunization.

• Others: Additional product types in the CDMO space.

Scale of Operation Insights

• Commercial Scale: Large-scale production targeting market supply.

• Clinical Scale: Smaller scale operations focused on clinical trial batches.

Therapeutic Area Insights

• Oncology: Treatments related to cancer.

• Cardiovascular Diseases: Medications targeting heart and blood vessel conditions.

• Infectious Diseases: Medicines for bacterial, viral, and other infections.

• Central Nervous System (CNS) Disorders: Drugs addressing neurological conditions.

• Others: Additional therapeutic areas covered by CDMOs.

Regional Insights

• North India

• South India

• East India

• West India

Summary: The dominant region is South India, which holds the largest market share driven by its advanced pharmaceutical infrastructure and investments. The entire India CDMO market is expected to grow at a CAGR of 7.7% during the forecast period.

India Cdmo Market Key Players

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

India Cdmo Market Recent Developments & News

In February 2025, Granules India acquired Swiss CDMO Senn Chemicals AG for CHF 20 Million (approx. INR 192.5 Crore), marking its entry into peptide therapeutics and enhancing its European market presence.

In December 2024, Akums Drugs and Pharmaceuticals partnered with a global pharma company to supply oral liquid formulations for the European market, under a Euro 200 million agreement effective from 2027, with regulatory approvals anticipated by 2026. These strategic moves support the expanding India CDMO market.

India Cdmo Market Key Highlights of the Report

• Comprehensive quantitative analysis of India CDMO market segments and forecasts from 2019-2033.

• Detailed insights into market drivers, challenges, and opportunities.

• Porter's five forces analysis to assess industry competitiveness and attractiveness.

• Competitive landscape with key player positioning and strategic insights.

• Segment-wise market assessment by service type, type, scale of operation, and therapeutic area.

• Regional market analysis covering North, South, East, and West India.

Get Your Customized Market Report Instantly: https://www.imarcgroup.com/request?type=report&id=30719&flag=E

Customization Note: If you require any specific information not covered within this report’s scope, we will provide it as part of the customization.

About Us

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel: (D) +91 120 433 0800

United States: +1-201971-6302